Objective：To evaluate the antiplatelet efficacy of ticagrelor in patients after off-pump coronary artery bypass graft（OPCABG）surgery and observe its clinical outcomes. Methods：A total of 90 patients undergoing OPCABG successfully in the First Affiliated Hospital of NMU during May 2015 to June 2016 were enrolled in this study. Patients were randomly divided into three groups. In the first day after surgery，group A was given clopidogrel（75 mg，1/day，oral）；group B was given ticagrelor（90 mg，2/day，oral）；group C was given half amount ticagrelor（45 mg，2/day，oral）. The three groups took aspirin standard dose（100 mg，1/day）at the same time. In 5 to 7 days after OPCABG，platelet inhibition（PI）rate induced by arachidonic acid（AA）and adenosine diphosphate（ADP）（PIADP and PIAA）by TEG was monitored to compare antiplatelet efficacy of the three groups. Major adverse cardiac events（MACE），bleeding events and related adverse reactions were also compared between the groups to evaluate the clinical effect. Results：Compared with group A，PIADP（%）of group B and group C were significantly increased（83.8 ± 17.6 vs. 60.5 ± 25.6，P=0.001；77.9 ± 24.6 vs. 60.5 ± 25.6，P=0.013，respectively）. There was no obvious difference of PIADP（%）between group B and group C（77.9 ± 24.6 vs. 83.8 ± 17.6，P > 0.05）. The three groups were not seen obvious MACE. Compared with group A，incidence of bleeding events in group B was increased，but there was no statistically significant difference（23.3% vs. 16.6%，P > 0.05）. Conclusion：Ticagrelor treatment as antiplatelet therapy in patients after OPCABG was effective and safe，and its antiplatelet efficacy was superior to clopidogrel.